Quantitative N-Glycan Mapping of Glycoprotein Therapeutics by HPAEC-PAD: Glycosylation Characteristics of Different Recombinant Human EPO Products View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2010-06-02

AUTHORS

Sebastian Kandzia , Nicolas Grammel , Eckart Grabenhorst , Harald S. Conradt

ABSTRACT

The consistent and appropriate control of the quality of N-linked oligosaccharides of recombinant glycoproteins during fermentation is a major issue in successful commercial protein manufacture, and regulatory authorities (FDA, EMEA) put high requirements on the quality and reproducibility of biopharmaceutical products. The glycosylation pattern of a therapeutic glycoprotein is influenced by cell type and cell culture environment (e.g. age of batch, glucose limitation, oxygen starvation, intracellular ammonium ion accumulation, pH changes). Glycosylation is the most complex post-translational modification made by animal cells, which makes a vital contribution to the biological activity and therapeutic efficacy of pharmaceutical glycoproteins (Grabenhorst and Conradt, 1999; Nimtz et al., 1993).GlycoThera has developed quantitative oligosaccharide mapping procedures (HPAEC-PAD) that are highly specific, sensitive (LOQ < 10 pmol), precise (CV ≤ 2%, n = 6), accurate (recovery of di-, tri- and tetrasialylated structures 97–103%) and robust in routine use (under cGMP regulations) for the quality control of recombinant glycoprotein therapeutics (drug substance and drug product batch release; assessment of lot-to-lot consistency, safety and long-term stability), requiring only low μg quantities of protein (e.g. 1 μg of EPO). HPAEC-PAD mapping of glycans is the only method for oligosaccharide analysis without requiring prior chemical derivatisation and will be described in the forthcoming edition of the European Pharmacopoeia in a separate chapter. Additionally, on-line desalted fractions obtained after HPAEC-PAD equipped with a carbohydrate membrane desalter (Dionex Corporation, Sunnyvale, CA, USA) are analysed by mass spectrometric methods; typically 1–5 pmol of oligosaccharide material is used for MS analysis. More... »

PAGES

867-871

Book

TITLE

Cells and Culture

ISBN

978-90-481-3418-2
978-90-481-3419-9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-90-481-3419-9_152

DOI

http://dx.doi.org/10.1007/978-90-481-3419-9_152

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020382233


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "GlycoThera GmbH, 38124, Braunschweig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "GlycoThera GmbH, 38124, Braunschweig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kandzia", 
        "givenName": "Sebastian", 
        "id": "sg:person.01115476110.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115476110.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlycoThera GmbH, 38124, Braunschweig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "GlycoThera GmbH, 38124, Braunschweig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grammel", 
        "givenName": "Nicolas", 
        "id": "sg:person.01047362710.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047362710.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlycoThera GmbH, 38124, Braunschweig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "GlycoThera GmbH, 38124, Braunschweig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grabenhorst", 
        "givenName": "Eckart", 
        "id": "sg:person.01313334742.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313334742.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlycoThera GmbH, 38124, Braunschweig, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "GlycoThera GmbH, 38124, Braunschweig, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Conradt", 
        "givenName": "Harald S.", 
        "id": "sg:person.01346153110.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346153110.13"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2010-06-02", 
    "datePublishedReg": "2010-06-02", 
    "description": "The consistent and appropriate control of the quality of N-linked oligosaccharides of recombinant glycoproteins during fermentation is a major issue in successful commercial protein manufacture, and regulatory authorities (FDA, EMEA) put high requirements on the quality and reproducibility of biopharmaceutical products. The glycosylation pattern of a therapeutic glycoprotein is influenced by cell type and cell culture environment (e.g. age of batch, glucose limitation, oxygen starvation, intracellular ammonium ion accumulation, pH changes). Glycosylation is the most complex post-translational modification made by animal cells, which makes a vital contribution to the biological activity and therapeutic efficacy of pharmaceutical glycoproteins (Grabenhorst and Conradt, 1999; Nimtz et al., 1993).GlycoThera has developed quantitative oligosaccharide mapping procedures (HPAEC-PAD) that are highly specific, sensitive (LOQ < 10 pmol), precise (CV \u2264 2%, n = 6), accurate (recovery of di-, tri- and tetrasialylated structures 97\u2013103%) and robust in routine use (under cGMP regulations) for the quality control of recombinant glycoprotein therapeutics (drug substance and drug product batch release; assessment of lot-to-lot consistency, safety and long-term stability), requiring only low \u03bcg quantities of protein (e.g. 1\u2009\u03bcg of EPO). HPAEC-PAD mapping of glycans is the only method for oligosaccharide analysis without requiring prior chemical derivatisation and will be described in the forthcoming edition of the European Pharmacopoeia in a separate chapter. Additionally, on-line desalted fractions obtained after HPAEC-PAD equipped with a carbohydrate membrane desalter (Dionex Corporation, Sunnyvale, CA, USA) are analysed by mass spectrometric methods; typically 1\u20135 pmol of oligosaccharide material is used for MS analysis.", 
    "editor": [
      {
        "familyName": "Noll", 
        "givenName": "Thomas", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-90-481-3419-9_152", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-90-481-3418-2", 
        "978-90-481-3419-9"
      ], 
      "name": "Cells and Culture", 
      "type": "Book"
    }, 
    "keywords": [
      "glycoprotein therapeutics", 
      "HPAEC-PAD", 
      "complex post-translational modifications", 
      "carbohydrate membrane desalter", 
      "post-translational modifications", 
      "recombinant glycoprotein therapeutics", 
      "mass spectrometric method", 
      "chemical derivatisation", 
      "pharmaceutical glycoproteins", 
      "animal cells", 
      "spectrometric method", 
      "recombinant glycoproteins", 
      "therapeutic glycoproteins", 
      "glycosylation pattern", 
      "glycosylation characteristics", 
      "quantity of protein", 
      "MS analysis", 
      "glycan mapping", 
      "cell types", 
      "protein manufacture", 
      "oligosaccharide analysis", 
      "EPO products", 
      "biological activity", 
      "culture environment", 
      "cell culture environment", 
      "biopharmaceutical products", 
      "European Pharmacopoeia", 
      "glycoprotein", 
      "oligosaccharide material", 
      "derivatisation", 
      "products", 
      "glycosylation", 
      "therapeutics", 
      "protein", 
      "quality control", 
      "glycans", 
      "desalter", 
      "fermentation", 
      "mapping", 
      "cells", 
      "materials", 
      "oligosaccharides", 
      "reproducibility", 
      "pmol", 
      "Pharmacopoeia", 
      "vital contribution", 
      "modification", 
      "appropriate controls", 
      "manufacture", 
      "mapping procedure", 
      "method", 
      "activity", 
      "lines", 
      "therapeutic efficacy", 
      "patterns", 
      "analysis", 
      "fraction", 
      "separate chapter", 
      "only method", 
      "control", 
      "environment", 
      "quantity", 
      "types", 
      "chapter", 
      "contribution", 
      "procedure", 
      "characteristics", 
      "use", 
      "major issue", 
      "regulatory authorities", 
      "requirements", 
      "high requirements", 
      "quality", 
      "forthcoming edition", 
      "routine use", 
      "efficacy", 
      "issues", 
      "edition", 
      "authorities", 
      "successful commercial protein manufacture", 
      "commercial protein manufacture", 
      "GlycoThera", 
      "quantitative oligosaccharide mapping procedures", 
      "oligosaccharide mapping procedures", 
      "HPAEC-PAD mapping", 
      "prior chemical derivatisation", 
      "membrane desalter", 
      "Different Recombinant Human EPO Products", 
      "Recombinant Human EPO Products", 
      "Human EPO Products"
    ], 
    "name": "Quantitative N-Glycan Mapping of Glycoprotein Therapeutics by HPAEC-PAD: Glycosylation Characteristics of Different Recombinant Human EPO Products", 
    "pagination": "867-871", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020382233"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-90-481-3419-9_152"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-90-481-3419-9_152", 
      "https://app.dimensions.ai/details/publication/pub.1020382233"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2021-11-01T18:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/chapter/chapter_102.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-90-481-3419-9_152"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-90-481-3419-9_152'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-90-481-3419-9_152'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-90-481-3419-9_152'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-90-481-3419-9_152'


 

This table displays all metadata directly associated to this object as RDF triples.

171 TRIPLES      23 PREDICATES      114 URIs      107 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-90-481-3419-9_152 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N454c5613eae04479beb6061e2c1b7399
4 schema:datePublished 2010-06-02
5 schema:datePublishedReg 2010-06-02
6 schema:description The consistent and appropriate control of the quality of N-linked oligosaccharides of recombinant glycoproteins during fermentation is a major issue in successful commercial protein manufacture, and regulatory authorities (FDA, EMEA) put high requirements on the quality and reproducibility of biopharmaceutical products. The glycosylation pattern of a therapeutic glycoprotein is influenced by cell type and cell culture environment (e.g. age of batch, glucose limitation, oxygen starvation, intracellular ammonium ion accumulation, pH changes). Glycosylation is the most complex post-translational modification made by animal cells, which makes a vital contribution to the biological activity and therapeutic efficacy of pharmaceutical glycoproteins (Grabenhorst and Conradt, 1999; Nimtz et al., 1993).GlycoThera has developed quantitative oligosaccharide mapping procedures (HPAEC-PAD) that are highly specific, sensitive (LOQ < 10 pmol), precise (CV ≤ 2%, n = 6), accurate (recovery of di-, tri- and tetrasialylated structures 97–103%) and robust in routine use (under cGMP regulations) for the quality control of recombinant glycoprotein therapeutics (drug substance and drug product batch release; assessment of lot-to-lot consistency, safety and long-term stability), requiring only low μg quantities of protein (e.g. 1 μg of EPO). HPAEC-PAD mapping of glycans is the only method for oligosaccharide analysis without requiring prior chemical derivatisation and will be described in the forthcoming edition of the European Pharmacopoeia in a separate chapter. Additionally, on-line desalted fractions obtained after HPAEC-PAD equipped with a carbohydrate membrane desalter (Dionex Corporation, Sunnyvale, CA, USA) are analysed by mass spectrometric methods; typically 1–5 pmol of oligosaccharide material is used for MS analysis.
7 schema:editor N7c762fb2e7b9418e811efaa745ed1735
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N412ce5376ad642f3b01acc8e2aa59335
12 schema:keywords Different Recombinant Human EPO Products
13 EPO products
14 European Pharmacopoeia
15 GlycoThera
16 HPAEC-PAD
17 HPAEC-PAD mapping
18 Human EPO Products
19 MS analysis
20 Pharmacopoeia
21 Recombinant Human EPO Products
22 activity
23 analysis
24 animal cells
25 appropriate controls
26 authorities
27 biological activity
28 biopharmaceutical products
29 carbohydrate membrane desalter
30 cell culture environment
31 cell types
32 cells
33 chapter
34 characteristics
35 chemical derivatisation
36 commercial protein manufacture
37 complex post-translational modifications
38 contribution
39 control
40 culture environment
41 derivatisation
42 desalter
43 edition
44 efficacy
45 environment
46 fermentation
47 forthcoming edition
48 fraction
49 glycan mapping
50 glycans
51 glycoprotein
52 glycoprotein therapeutics
53 glycosylation
54 glycosylation characteristics
55 glycosylation pattern
56 high requirements
57 issues
58 lines
59 major issue
60 manufacture
61 mapping
62 mapping procedure
63 mass spectrometric method
64 materials
65 membrane desalter
66 method
67 modification
68 oligosaccharide analysis
69 oligosaccharide mapping procedures
70 oligosaccharide material
71 oligosaccharides
72 only method
73 patterns
74 pharmaceutical glycoproteins
75 pmol
76 post-translational modifications
77 prior chemical derivatisation
78 procedure
79 products
80 protein
81 protein manufacture
82 quality
83 quality control
84 quantitative oligosaccharide mapping procedures
85 quantity
86 quantity of protein
87 recombinant glycoprotein therapeutics
88 recombinant glycoproteins
89 regulatory authorities
90 reproducibility
91 requirements
92 routine use
93 separate chapter
94 spectrometric method
95 successful commercial protein manufacture
96 therapeutic efficacy
97 therapeutic glycoproteins
98 therapeutics
99 types
100 use
101 vital contribution
102 schema:name Quantitative N-Glycan Mapping of Glycoprotein Therapeutics by HPAEC-PAD: Glycosylation Characteristics of Different Recombinant Human EPO Products
103 schema:pagination 867-871
104 schema:productId N1aff470a5b044fc5acdc5d05a38ec960
105 Ndfe8b4c61aaf4c6d97941f53c59fb687
106 schema:publisher Ne938d9f2c6be4996b330d063c28995e4
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020382233
108 https://doi.org/10.1007/978-90-481-3419-9_152
109 schema:sdDatePublished 2021-11-01T18:45
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher Nd40697de6f854cc78176b81db93f2545
112 schema:url https://doi.org/10.1007/978-90-481-3419-9_152
113 sgo:license sg:explorer/license/
114 sgo:sdDataset chapters
115 rdf:type schema:Chapter
116 N1aff470a5b044fc5acdc5d05a38ec960 schema:name dimensions_id
117 schema:value pub.1020382233
118 rdf:type schema:PropertyValue
119 N412ce5376ad642f3b01acc8e2aa59335 schema:isbn 978-90-481-3418-2
120 978-90-481-3419-9
121 schema:name Cells and Culture
122 rdf:type schema:Book
123 N44ecb78333294672b819d162be500d83 schema:familyName Noll
124 schema:givenName Thomas
125 rdf:type schema:Person
126 N454c5613eae04479beb6061e2c1b7399 rdf:first sg:person.01115476110.75
127 rdf:rest N5fd7eb5673a24db4985e8f1cc60dbd3a
128 N5fd7eb5673a24db4985e8f1cc60dbd3a rdf:first sg:person.01047362710.01
129 rdf:rest N8c5d989488444a41ba3aa1df09f9e7eb
130 N7c762fb2e7b9418e811efaa745ed1735 rdf:first N44ecb78333294672b819d162be500d83
131 rdf:rest rdf:nil
132 N89af1d3e49d44e9498df5c0bfdc1ad5a rdf:first sg:person.01346153110.13
133 rdf:rest rdf:nil
134 N8c5d989488444a41ba3aa1df09f9e7eb rdf:first sg:person.01313334742.81
135 rdf:rest N89af1d3e49d44e9498df5c0bfdc1ad5a
136 Nd40697de6f854cc78176b81db93f2545 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 Ndfe8b4c61aaf4c6d97941f53c59fb687 schema:name doi
139 schema:value 10.1007/978-90-481-3419-9_152
140 rdf:type schema:PropertyValue
141 Ne938d9f2c6be4996b330d063c28995e4 schema:name Springer Nature
142 rdf:type schema:Organisation
143 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
144 schema:name Biological Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
147 schema:name Biochemistry and Cell Biology
148 rdf:type schema:DefinedTerm
149 sg:person.01047362710.01 schema:affiliation grid-institutes:None
150 schema:familyName Grammel
151 schema:givenName Nicolas
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047362710.01
153 rdf:type schema:Person
154 sg:person.01115476110.75 schema:affiliation grid-institutes:None
155 schema:familyName Kandzia
156 schema:givenName Sebastian
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115476110.75
158 rdf:type schema:Person
159 sg:person.01313334742.81 schema:affiliation grid-institutes:None
160 schema:familyName Grabenhorst
161 schema:givenName Eckart
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313334742.81
163 rdf:type schema:Person
164 sg:person.01346153110.13 schema:affiliation grid-institutes:None
165 schema:familyName Conradt
166 schema:givenName Harald S.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346153110.13
168 rdf:type schema:Person
169 grid-institutes:None schema:alternateName GlycoThera GmbH, 38124, Braunschweig, Germany
170 schema:name GlycoThera GmbH, 38124, Braunschweig, Germany
171 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...